An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.

Start Date09 Jun 2025

Sponsor / Collaborator

Shenzhen Yinuowei Medical Technology Co., Ltd.

NCT05756556

/ SuspendedPhase 2

A Phase 2a, Open-label Study of T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

This study will evaluate the efficacy and safety of T3011 in combination with Cobimetinib in patients with advanced melanoma.

Start Date30 Jun 2024

Sponsor / Collaborator

Shenzhen Yinuowei Medical Technology Co., Ltd.

NCT06283303

/ Unknown statusPhase 1IIT

A Clinical Study to Evaluate the Safety and Efficacy of Herpes Virus T3011 Injection in Combination With Toripalimab and Regorafenib in Patients With Liver Metastases From Colorectal Cancer

This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.

Start Date02 Apr 2024

Sponsor / Collaborator

China Medical University

[+1]

100 Clinical Results associated with MVR-T3011

100 Translational Medicine associated with MVR-T3011

100 Patents (Medical) associated with MVR-T3011

Literatures (Medical) associated with MVR-T3011

01 Mar 2024·Heliyon

Impact of additives from moringa stenopetela leaf extract and ethanol on the emission characteristics and performance of soybean biodiesel for single cylinder CI engine

Article

Author: Bezabih, Atsedemariam Ayalew ; Zeleke, Dinku Seyoum

The study investigates the effect of ethanol and Moringa antioxidant on the performance and emission characteristics of a Soybean biodiesel blend (B15, B20, and B25) using a direct injection, four-stroke, naturally aspirated, water-cooled single-cylinder diesel engine equipped with SCADA software. The effect of reaction parameters on FAEE yield such as, time, catalyst concentration, molar ratio of alcohol to oil, and blending quality, was optimized using the one factor at a time experimental technique. The maximum yield of 97.8% biodiesel was produced at the ideal catalyst concentration, blending quality, alcohol to oil molar ratio, and time of 1 h, are 1%, 12:1, and 500 rpm, respectively. The Rancimat method was used to assess the oxidative stability of pure biodiesel after the natural antioxidant (extracted from Moringa leaf) was added at concentrations of 1500, 2500, 3500, and 4500 ppm. The addition of antioxidants to biodiesel significantly increased its induction time from 4.52 to 19.98 h. Brake-thermal efficiency increased by 4.4% whereas brake-specific fuel consumptions decreased by 4.6% for B15E2M (15% SB+2E + M) when compared to B15. Emission characteristics of B25E2M showed higher reduction of CO, HC and NOx by 20.27%, 8% and 7% as compared to the B25 respectively. The physicochemical qualities, performance, and emission characteristics of B15 blends with additive are generally comparable to those of diesel fuel. In conclusion, both additives significantly improved the combustion performance of soybean biodiesel blend.

01 Dec 2023·The Science of the total environment

Carbonation of steel slag at low CO2 concentrations: Novel biochar cold-bonded steel slag artificial aggregates

Article

Author: Xie, Guangming ; Xing, Feng ; Liu, Guang ; Li, Zhenlin ; Zhang, Weizhuo ; Liu, Jun ; Zeng, Canrong

Carbonation technology resolves the volume expansion of steel slag by combining CO₂ with f-CaO, but the previous stringent carbonation conditions (99%vol) significantly limit the application prospect of steel slag. To achieve the carbonation of steel slag at lower CO₂ concentrations, a novel cold-bonded artificial aggregates (CASSAs) based on steel slag and biochar is produced in this paper. The carbon capture capacities of CASSAs with different biochar contents (5 wt%, 10 wt%, and 15 wt%) are investigated in a low-CO₂ concentration environment (10.79 % vol) and natural environment using the porosity and CO₂ adsorption capacity of biochar. The changes in the performance of CASSAs before and after carbonation are investigated at different curing ages (7 d and 28 d). The results reveal that biochar increases the pores of the CASSAs. At 7 d, B15 achieves complete carbonation at low concentrations and can uptake 6.5 wt% of CO₂. CO₂ adsorption capacity by biochar in the natural environment facilitates the diffusion of CO₂ in CASSAs. Regarding mechanical properties, the addition of biochar makes B15 at 7 d half as strong as B0, but B15 exhibits long-term strength development. B15 at 7 d has a strength of 8.49 MPa after carbonation, which is almost the same as B0. In addition, B15 achieves a net CO₂ emission of -39.9 kg/ton. This study combines biochar with CASSAs to provide a potential method to carbonate steel slag at low CO₂ concentrations. A new methodology was also used to quantitatively assess the ability of biochar CASSAs to solidify CO₂ under low concentration conditions and natural environments from a macroscopic perspective. Biochar CASSAs have great potential to realize resource utilization and carbon capture from steel slag.

01 Mar 2023·European journal of medicinal chemistry

Novel spiro[chromanone-2,4′-piperidine]-4-one derivatives as potential inhibitors of fatty acid synthesis in pathogens: Design, synthesis, and biological evaluation

Article

Author: Jin-Hong Hu ; Pei-Yi Wang ; Shuai-Shuai Liu ; Xiang Zhou ; Song Yang ; Dan Zeng ; Zhi-Bing Wu ; Bin-Xin Yang ; Tai-Hong Zhang ; Jie Yang ; Li-Wei Liu

Bacterial survival depends on membrane lipid homeostasis that enables to regulate lipid composition to adapt and optimize their growth in diverse environments. Therefore, the development of inhibitors that interfere with the bacterial fatty acid synthesis process is considered to be a promising tactic. In this study, 58 novel spirochromanone derivatives were prepared and their structure-activity relationship (SAR) was investigated. The bioassay results showed that all most of the compounds showed excellent biological activities, exampled by compounds B₁₄, C₁, B₁₅, and B₁₃, which had outstanding inhibitory activities toward various pathogenic bacteria with EC₅₀ values of 0.78 μg/mL ∼3.48 μg/mL. Preliminary antibacterial behavior was studied by a series of biochemical assays including, but not limited to, fluorescence imaging patterns, GC-MS analysis, TEM images, and fluorescence titration experiments. Notably, compound B₁₄ decreased the lipid content of the cell membrane, and increased cell membrane permeability, thereby destroying the integrity of the bacterial cell membrane. Further qRT-PCR results indicated that compound B₁₄ interfered with the mRNA expression levels of fatty acid synthesis process-related genes including ACC, ACP, and Fab family genes. Herein, we highlight the promising bactericidal skeleton based on the spiro[chromanone-2,4'-piperidine]-4-one as a potential inhibitor of fatty acid synthesis.

News (Medical) associated with MVR-T3011

23 Oct 2026

·www.prnewswire.com

ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress. These presentations covered three key patient populations: 1) BCG-unresponsive high-risk carcinoma in situ (CIS); 2) BCG-unresponsive high-risk papillary (Ta/T1) tumors; and 3) BCG-naïve papillary (Ta/T1) tumors. The updated data showed encouraging clinical activity across the three patient populations, highlighting MVR-T3011's broad therapeutic potential in bladder cancer and underscoring ImmVira's comprehensive and long-term strategic commitment to this clinical landscape. As of the August 31, 2026 data cutoff, the updated poster presentations highlight the following key efficacy results: Updated Phase II Study of MVR-T3011 in High-risk BCG-Unresponsive CIS NMIBC (E-poster FPN: 4792eP; NCT06971614) The study enrolled 20 patients. Among them, 19 were evaluable for efficacy, receiving intravesical MVR-T3011 at either a 2×109 PFU (9 patients) or a 1×1010 PFU (10 patients) dose. The 1×1010 PFU cohort achieved 88.9% and 87.5% complete response rate (CRR) at 6 months and 9 months respectively. The anytime CRR for the 1×1010 PFU dose reached 90% (9/10). This demonstrated superior response rates compared to the 2×109 PFU cohort, which achieved a 66.7% (6/9) anytime CRR. Updated Phase II Study of MVR-T3011 in High-risk BCG-Unresponsive Papillary NMIBC (E-poster FPN: 4793eP; NCT06971614) This cohort included 17 evaluable patients treated with the 2×109 PFU dose of MVR-T3011. Patients achieved a 12-month recurrence-free survival (RFS) rate of 75.1%. Notably, 6 patients (6/17, 35%) successfully completed the full 2-year treatment course and remained recurrence-free. Intravesical MVR-T3011 in BCG-Naïve High-Risk Papillary NMIBC (E-poster FPN: 4790eP) Evaluating the therapy in a frontline setting, 15 patients were enrolled with 14 patients were evaluable. Patients were treated at the 1×1010 PFU dose. Early results showcased robust clinical activity, with patients achieving a 92.9% RFS rate at 3 months. The RFS rate remained strong at 78.6% at 6 months, and 69.8% at both 9 and 12 months. Across all three evaluated patient cohorts, MVR-T3011 demonstrated an excellent tolerability profile consistent with earlier clinical findings. The therapy maintained a highly manageable safety record even at the optimized higher doses, with no Grade 4 or higher treatment-related adverse events reported. "Following our earlier presentation at ASCO 2026, we are highly encouraged to see the continuing clinical momentum and explosive potential of MVR-T3011 across broader NMIBC indications at this year's ESMO Congress," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "These updated data further validate the therapy's ability to provide a durable, highly effective, well-tolerated, and safe treatment option for bladder cancer patients. We remain fully committed to accelerating its clinical development to establish MVR-T3011 as an affordable, foundational novel treatment choice for bladder cancer patients worldwide, while actively expanding its clinical evaluation into late-stage muscle-invasive bladder cancer (MIBC) to offer a novel immunotherapy that enables bladder preservation and improves quality of life." About MVR-T3011 MVR-T3011 represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations. About ImmVira ImmVira is a global, clinical-demand-driven biotechnology company dedicated to the discovery, development, manufacturing, and commercialization of novel oncolytic immunotherapies powered by its proprietary bioengineering platform. The company strategically builds a differentiated pipeline that balances breakthrough innovation with clinical feasibility, targeting major oncological indications including bladder cancer, intracranial tumors, and various refractory solid tumors. Driven by the strategic vision to become a global leader in cancer immunotherapy—specifically across all lines of bladder cancer treatment—ImmVira adopts a rational and adaptive global R&D approach. Leveraging deep expertise in bioengineering modification, ImmVira integrates multiple mechanisms including genetic modification, tumor microenvironment remodeling, and targeted delivery. This enables the development of potential best-in-class oncolytic immunotherapies alongside robust combination strategies with immune checkpoint inhibitors, chemotherapy, and other targeted agents. Supported by fully integrated capabilities spanning target discovery, process development, commercial-scale GMP manufacturing, and global multi-center clinical filings, ImmVira is strategically accelerating the clinical translation and commercialization of its core pipeline to deliver transformative treatments to patients worldwide. SOURCE ImmVira 21% more press release views with Request a Demo

Clinical ResultImmunotherapyPhase 2

01 Jun 2026

·www.prnewswire.com

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the data cut-off on January 31, 2026, the optimized dose of MVR-T3011 achieved a 100% complete response rate (CRR) in BCG-unresponsive carcinoma in situ (CIS) and a durable 90% recurrence-free survival (RFS) in papillary (Ta/T1) tumors[1]. While intravesical instillation of Bacillus Calmette-Guérin (BCG) remains the standard of care for high-risk NMIBC-representing 75% of all newly diagnosed bladder cancer cases, a global BCG shortage and high rates of non-response leave a significant patient population without effective options. MVR-T3011 was developed with the goal of delivering potent local and systemic anti-tumor immunity directly within the bladder, offering a potential organ-preserving treatment option for this high-need population. The ongoing trial enrolled 46 patients in total with pathologically confirmed BCG-unresponsive high-risk NMIBC. Patients received intravesical MVR-T3011 at one of two dose levels: Lower-dose group (2×109 PFU): Induction course followed by maintenance dosing over two years (n=25). Higher-dose group (1×1010 PFU): Induction course followed by maintenance dosing over two years (n=21). The results demonstrate that MVR-T3011 achieved meaningful clinical efficacy and a favorable safety profile across both carcinoma in situ (CIS) and papillary (Ta/T1) disease settings： In the CIS cohort, the higher-dose 1×1010 PFU regimen achieved a 100% complete response rate (CRR) at 3 months, 6 months, and 9 months, as well as at any assessed timepoint— a marked step up from the lower-dose 2×109 PFU cohort, which achieved a 66.7% CR rate at any timepoint (with timepoint-specific CRRs of 55.6% at 3 months and 75.0% at 6 months). The 12-month CRR for the 1×1010 PFU cohort has not yet been reached, with follow-up ongoing. In the papillary (Ta/T1) cohort, the 2×109 PFU dose delivered a durable 12-month recurrence-free survival (RFS) of 74.0%, an already strong outcome; at the higher 1×1010 PFU dose, 9-month RFS reached 90.0%, with longer-duration follow-up ongoing. Across all 46 patients treated, MVR-T3011 demonstrated a manageable safety profile consistent with prior observations. Importantly, the higher-dose 1×1010 PFU cohort showed a safety profile consistent with the lower-dose 2×109 PFU cohort, with no Grade 4 or 5 TEAEs reported across either dose level, or no deaths attributable to treatment. "The presentation of these Phase IIa results at ASCO 2026 marks a meaningful milestone for ImmVira and for the broader NMIBC community," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "MVR-T3011 has demonstrated great therapeutic potential through both direct anti-tumor activity in CIS and immune suppression in papillary (Ta/T1) disease. This represents a synergy of direct oncolysis and immune activation, further enhanced by the integrated effects of exogenous IL-12 and PD-1 antibody expressions within tumor cells. We are committed to rapidly advancing our clinical program to reach broader bladder cancer patient populations and provide meaningful treatment alternatives for those in need. About MVR-T3011 MVR-T3011, represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations. About ImmVira ImmVira is a clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. We have strategically designed, self-discovered, and built a risk-balanced product portfolio that comprised two oncolytic immunotherapy candidates for solid tumors and five engineered exosome assets poised for clinical application or direct commercialization. Driven by our vision to become a global leader in the full spectrum of bladder cancer treatment development and unlock the therapeutical potential of oncolytic immunotherapy in head and neck squamous cell carcinoma (HNSCC), we have adopted a rationalized, adaptive approach to advance oncolytic immunotherapy candidates with high clinical potential globally. In parallel, leveraging our deep expertise in biological engineering, we have pioneered development of engineered exosome candidates targeting chronic, hard-to-treat diseases as well as age-related conditions. These selected engineered exosome assets are being accelerated through differentiated regulatory pathways to enable expedited commercialization and generate sustainable cash flows that will fuel our broader drug development efforts. SOURCE ImmVira Group 21% more press release views with Request a Demo

Clinical ResultImmunotherapyASCOPhase 2Phase 1

27 Feb 2026

·www.prnewswire.com

ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference

SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself, means that a substantial number of patients cannot access effective BCG treatment. Therefore, it is essential to seek better alternative therapies to BCG in order to meet clinical needs. Based on this, ImmVira Group is further expanding the clinical trial of its core oncolytic virus product, MVR-T3011—originally targeting BCG-unresponsive high-risk bladder cancer—to further include BCG-naïve bladder cancer patients. On February 26, 2026, at the ASCO GU 2026 Conference in San Francisco, California, ImmVira Group announced preliminary positive results from its clinical trial evaluating MVR-T3011, an oncolytic virus, in BCG-naïve high-risk papillary Ta/T1 NMIBC patients for its leading oncolytic virus product, MVR-T3011, via intravesical administration. The data were presented in a poster at the Conference. In the study involving 18 BCG-naïve high-risk papillary Ta/T1 NMIBC patients treated with intravesical MVR-T3011 at two dose levels: 2x109 PFU (3 patients) and 1x1010 PFU (15 patients), preliminary data as of December 31, 2025, demonstrated encouraging efficacy and durability. Among the 14 evaluable patients, the 12-month recurrence-free-survival (RFS) rate was 100% (3/3) at the 2x109 PFU dose level. At the 1x1010 PFU dose level, the 3-month RFS rate was 100% (11/11). The 6-month and 9-month RFS rates were 75% (3/4) and 66.7% (2/3), respectively, but these data are preliminary, given the small patient numbers reaching those timepoints. Consistent with BCG-unresponsive clinical data, MVR-T3011 maintained a favorable safety profile in this study with most treatment-emergent adverse events (TEAEs) being at Grades 1 or 2. No treatment-related adverse events (TRAEs) were observed. Bladder cancer ranks as the ninth most prevalent cancer worldwide[1], with approximately 75% of cases classified as NMIBC. While Bacillus Calmette-Guerin (BCG) remains the current SOC for high-risk NMIBC, global shortages have limited its availability. As a result, oncolytic immunotherapy, which offers enhanced immune activation and potential durability, is emerging as a promising alternative. "We are highly encouraged by the preliminary efficacy and safety data from the study," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "MVR-T3011 shows its potential to serve as a reliable and widely accessible alternative to BCG, ultimately benefiting patients worldwide." Source: 1. GLOBOCAN 2022: Bladder cancer 9th most common worldwide About MVR-T3011 MVR-T3011, represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations. About ImmVira ImmVira is a clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. We have strategically designed, self-discovered, and built a risk-balanced product portfolio that comprised two oncolytic immunotherapy candidates for solid tumors and five engineered exosome assets poised for clinical application or direct commercialization. Driven by our vision to become a global leader in the full spectrum of bladder cancer treatment development and unlock the therapeutical potential of oncolytic immunotherapy in head and neck squamous cell carcinoma (HNSCC), we have adopted a rationalized, adaptive approach to advance oncolytic immunotherapy candidates with high clinical potential globally. In parallel, leveraging our deep expertise in biological engineering, we have pioneered development of engineered exosome candidates targeting chronic, hard-to-treat diseases as well as age-related conditions. These selected engineered exosome assets are being accelerated through differentiated regulatory pathways to enable expedited commercialization and generate sustainable cash flows that will fuel our broader drug development efforts. SOURCE ImmVira Group 21% more press release views with Request a Demo

ImmunotherapyClinical ResultClinical Study

100 Deals associated with MVR-T3011

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	Phase 2	United States	Shenzhen Yinuowei Medical Technology Co., Ltd.	09 Jun 2025
Melanoma, Cutaneous Malignant	Phase 2	United States	Shenzhen Yinuowei Medical Technology Co., Ltd.	30 Jun 2024
Melanoma	Phase 2	China	Shenzhen Yinuowei Medical Technology Co., Ltd.	05 Jan 2024
Advanced cancer	Phase 2	China	Shenzhen Yinuowei Medical Technology Co., Ltd.	21 Feb 2022
Lung Cancer	Phase 2	China	Shenzhen Yinuowei Medical Technology Co., Ltd.	21 Feb 2022
Lymphoma	Phase 2	China	Shenzhen Yinuowei Medical Technology Co., Ltd.	21 Feb 2022
Malignant Pleural Mesothelioma	Phase 2	China	Shenzhen Yinuowei Medical Technology Co., Ltd.	21 Feb 2022
Colorectal Cancer	Phase 2	United States	Shenzhen Yinuowei Medical Technology Co., Ltd.	10 Aug 2021
Endometrial Carcinoma	Phase 2	United States	Shenzhen Yinuowei Medical Technology Co., Ltd.	10 Aug 2021
Ovarian Cancer	Phase 2	United States	Shenzhen Yinuowei Medical Technology Co., Ltd.	10 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2026	Phase 2	Non-Muscle Invasive Bladder Neoplasms	16	MVR-T3011 (2×10^9 PFU)	xfxhvabhry(mojmerotld) = igabbavrdz ujenaywzul (scucfmfzyp ) View more	Positive	23 Oct 2026
				MVR-T3011 (1×10^10 PFU)	xfxhvabhry(mojmerotld) = erlcixnaiv ujenaywzul (scucfmfzyp ) View more
ESMO2026	Phase 2	Non-Muscle Invasive Bladder Neoplasms	14	MVR-T3011	thbuvyhyij(pylzrgwbkd) = ybntthzvyl fxqxcnrkpz (joasrjoxvl, 59.1 - 99.0) View more	Positive	23 Oct 2026
NCT06427291 (ASCO2026)	Phase 2	Non-Muscle Invasive Bladder Neoplasms	43	MVR-T3011 (2×10^9 PFU)	wpzcztxaby(xetjuuicpz) = xtynaryccm gsqbdshous (opyumuhkeb ) View more	Positive	29 May 2026
				MVR-T3011 (1×10^10 PFU)	wpzcztxaby(wzuspofgtg) = mseqzwpiwi ewasmhzvpp (sjoofgvxcz ) View more
Company_Website Manual	Phase 1/2	Non-Muscle Invasive Bladder Neoplasms First line	18	MVR-T3011 2x10^9 PFU	pndtmyhyzd(grphsdbfxv) = bcwzhvrxpy yhwbdywvam (qpygjqkdpz )	Positive	27 Feb 2026
				MVR-T3011 1x10^10 PFU	pndtmyhyzd(grphsdbfxv) = elyuummfqd yhwbdywvam (qpygjqkdpz ) View more
NCT05602792 (Pubmed \| BMC Med)	Phase 1/2	Squamous Cell Carcinoma of Head and Neck \| Advanced Malignant Solid Neoplasm	87	T3011 (Part III)	xwdztawdve(lazhqpnfer) = cdrvluaekr pigukqzbxd (qelontphmi ) View more	Positive	20 Feb 2026
				T3011 (HNSCC)	xwdztawdve(lazhqpnfer) = wdathcolos pigukqzbxd (qelontphmi ) View more
PRNewswire \| NEWS Manual	Phase 2	Bladder Cancer	38	MVR-T3011 2x10^9 PFU (BCG-unresponsive papillary)	dwkkpvuyuk(vznfxnzxzf) = vrijvwjwjo vklyiuzvtw (bdzjogfvnf ) View more	Positive	03 Dec 2025
				MVR-T3011 1x10^10 PFU (BCG-unresponsive papillary)	dwkkpvuyuk(vznfxnzxzf) = kvoctubxek vklyiuzvtw (bdzjogfvnf ) View more
NCT06427291 (ESMO2024) Manual	Phase 1	Non-Muscle Invasive Bladder Neoplasms Second line	13	T3011 5x10^7 PFU	zloltsdocf(detisbdbkg) = xxodoigfpn jkfqmnacwm (bhhhtbooxv )	Positive	15 Sep 2024
				T3011 5x10^8 PFU	zloltsdocf(detisbdbkg) = ljlcklyuoj jkfqmnacwm (bhhhtbooxv )
NCT04780217 (PRNewswire) Manual	Phase 1	Neoplasms	18	MVR-T3011	lrogzmujek(cydptkcosm) = eyaytxsmgi efuotuqoav (dlgjfagenf ) View more	Positive	09 Nov 2023
NCT04780217 (ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	HR-positive/HER2-low Solid Tumors	10	MVR-T3011	owooueeoux(ttyjpmpbpr) = lgbvmsekbp kdxmlewljs (dmywukvbmh ) View more	Positive	31 May 2023
NCT04370587 (ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	HR-positive/HER2-low Solid Tumors	29	T3011	cgwruljhnq(dbuaekutpa) = 3.4% (1/29) qefxxhfmjf (zftpfwuaxw ) View more	Positive	26 May 2023
				T3011+Pembrolizumab

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis